--
You received this message because you are subscribed to the Google Groups "Edge Test Tool (ETT)" group.
To unsubscribe from this group and stop receiving emails from it, send an email to edge-test-too...@googlegroups.com.
To view this discussion visit https://groups.google.com/d/msgid/edge-test-tool/f50f37bf-8992-40a6-b4b1-efb6be947086n%40googlegroups.com.

To view this discussion visit https://groups.google.com/d/msgid/edge-test-tool/a48f7ed6-894b-4f27-8282-e8ac413a5070n%40googlegroups.com.
To view this discussion visit https://groups.google.com/d/msgid/edge-test-tool/d4839366-5477-43ca-90bb-b6aeca3ec64dn%40googlegroups.com.
So – I tried the self validation first just to confirm and this is what I still see


From: edge-te...@googlegroups.com <edge-te...@googlegroups.com>
On Behalf Of Sai Valluripalli
Sent: Tuesday, April 14, 2026 5:16 PM
To: Braeden Rai <braed...@gmail.com>
Cc: Edge Test Tool (ETT) <edge-te...@googlegroups.com>
Subject: Re: Any way to get some help on the B1 tests pending?
Security Notice: This is an EXTERNAL email. Please exercise caution and DO NOT open attachments or click links from unknown or unexpected senders.
Yes, did you test XDR 1 today? Are you still not able to pass?
On Tue, Apr 14, 2026 at 4:29 PM Braeden Rai <braed...@gmail.com> wrote:
Hello,
We seem to be encountering a similar or the same issue. We can receive messages just fine from cases like XDR 3, but XDR 1 is always stuck at pending, even when we see the message received successfully from our perspective.
Has there been any troubleshooting done on this?
Thanks,
Braeden
On Thursday, April 9, 2026 at 10:29:51 AM UTC-5 digitalh...@gmail.com wrote:
Will email you directly to address this issue
On Wed, Apr 8, 2026 at 5:09 PM Tim Hargan <harga...@gmail.com> wrote:
Can anyone actually follow up and look into this as to what is going on? I have been trying to get someone to look into this for months now - months with no useful help.
On Thursday, April 2, 2026 at 3:39:04 PM UTC-4 Tim Hargan wrote:
Yeah sending to us is not an issue
Disclaimer: The information contained in this transmission and any attachments may contain privileged and confidential information including patient information protected by federal and state privacy laws. This transmission is sent for the sole use of the intended recipient. If you are not the intended recipient, please immediately (1) notify the sender via reply email; (2) do not open or read the message or any attachments; and (3) delete this message and any attachments. The review, dissemination, distribution, or duplication of this transmission by anyone other than the intended recipient is strictly prohibited.